Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Merck KGaA's Erbitux (cetuximab) wins EC approval for first-line BRAF V600E-mutant metastatic colorectal cancer based on Ph3 data
Antibody, cancer, monoclonal antibody, colorectal cancer, BRAF V600E mutation, EGFR inhibitor, combination therapy - Read more

Biogen, Eisai win FDA approval for subcutaneous Leqembi (lecanemab) initiation therapy in Alzheimer's disease
Antibody, neurological, monoclonal antibody, Alzheimer's disease, anti-amyloid, subcutaneous delivery - Read more

Avere Therapeutics, NextCure, Hansoh Pharmaceutical merge publicly, license oral IL-23 drug AVR-001 for $120M upfront, $2.18B milestones
Reverse merger, licensing deal, autoimmune, small molecule, milestone payments, royalties - Read more

AstraZeneca, Dizal Pharmaceutical strike exclusive global lung cancer license deal, $600M upfront, up to $1.5B total
Licensing deal, oncology, small molecule, milestone payments, royalties - Read more

Spero Therapeutics licenses Innovent Biologics' CD40L antibody SP001 for autoimmune diseases, deal worth up to $1.1B
Licensing deal, autoimmune, antibody, rare disease, milestone payments, royalties - Read more

Chai Discovery, Novartis partner on AI-driven therapeutic antibody discovery across multiple targets
Research collaboration, AI/ML, drug discovery, antibody, R&D - Read more

Ardigen, VERAXA Biotech launch AI-driven partnership to optimize T cell engager and ADC drug discovery
Research collaboration, oncology, AI/ML, drug discovery, antibody, cell therapy - Read more

Summit Therapeutics sells ridinilazole to Biossil for $500K upfront, $104.5M milestones
Licensing deal, infectious disease, AI/ML, small molecule, milestone payments - Read more

Mylan sells up to $363M stake in Biocon, representing 5.64% of outstanding shares
Equity investment, secondary offering, commercialization, generics - Read more

Managing investigator grants across large portfolios isn't just a tracking problem — it's a trial oversight issue. Limited visibility into site and procedural-level liabilities makes it nearly impossible to accurately forecast investigator expenses, which can exceed 50% of a trial's budget. Incorrect billing and surprise invoices follow. 

The good news: sponsors already have the data they need to get this under control. 

Join Auxilius on July 29th at 10am ET to learn how leading pharma and biotech teams are managing investigator spend using data they already have, building data taxonomies to organize and harmonize it, and using automation to operate at scale.

Register here

GSK's Jemperli (dostarlimab) meets Ph2 primary endpoint in dMMR/microsatellite instability-high locally advanced rectal cancer, global submissions planned
Antibody, cancer, monoclonal antibody, colorectal cancer, PD-1 inhibitor, dMMR/MSI-H - Read more

Q32 Bio's bempikibart meets Ph2 goal, helping 40% of alopecia areata patients achieve significant hair regrowth
Antibody, autoimmune, monoclonal antibody, alopecia areata, IL-7/TSLP pathway inhibitor - Read more

Freenome's SimpleScreen CRC blood test shows improved sensitivity for colorectal cancer screening in pivotal validation study
Diagnostic test, cancer, liquid biopsy, colorectal cancer, cancer screening - Read more

Biogen's (diranersen) Ph2 results show tau-targeting antisense oligonucleotide slows decline in Alzheimer's disease
Antisense oligonucleotide, neurological, Alzheimer's disease, tau protein, small molecule - Read more

Ipsen's IQIRVO (elafibranor) hits primary endpoint in Ph3b trial for primary biliary cholangitis, achieving 85% alkaline phosphatase normalization
Small molecule, autoimmune, PPAR agonist, primary biliary cholangitis, ALP normalization, cholestasis - Read more

Chai Discovery raises $400M Series C to advance AI molecule models for drug discovery
AI/ML platform, drug discovery, antibody design, platform-enabled - Read more

Drug Farm completes $55M Series D first closing, advancing clinical and preclinical pipeline
Clinical-stage, first-in-class, preclinical, drug discovery - Read more

Draig Therapeutics raises $65M Series B to advance neuropsychiatric AMPA and GABAA receptor modulators
Neuropsychiatric, small molecule, clinical-stage, major depressive disorder - Read more

Erasca plans $500M public offering to fund RAS/MAPK pathway cancer therapy development
Clinical-stage, precision oncology, RAS/MAPK pathway, small molecule - Read more

Real Chemistry launches Anatomi AI platform to streamline healthcare commercialization across marketing and medical workflows
AI tools, healthcare commercialization, operational, competitive - Read more

FDA proposes streamlined "hub-and-spoke" registration rules to ease distributed manufacturing burdens for biopharma companies
Manufacturing, operational, regulatory, strategic - Read more

FDA releases final psychedelics guidance, signaling flexibility for Compass Pathways and Definium Therapeutics
Small molecule, neurological, regulatory, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Merck KGaA's EMD Serono mandates in-office work, risking 70 layoffs among remote R&D staff
Workforce restructuring, operational, cost reduction, strategic - Read more

Lupin Pharmaceuticals recalls 2.5M+ prescription eye drop bottles due to foreign substance contamination
Small molecule, ophthalmology, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here